All In Biotech

Drug Trial Radar · NCT02851797

Clinical Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy

Randomised, Double Blind, Placebo Controlled, Multicentre Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy

Last checked: Nov 19, 2026Latest source record: Feb 2, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 179 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

179

Actual

Start

Jun 6, 2017

Primary completion

Feb 22, 2022

Study completion Feb 22, 2022

Sponsor

Lead sponsor
ItalfarmacoIndustry
Sponsor type
Industry
Collaborators
Syneos Health
First posted
Aug 2, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 6 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objective The primary objective of the study was to establish the effects of givinostat versus placebo administered chronically over 18 months to slow disease progression in ambulant DMD subjects. Secondary Objectives The secondary objectives of this study were: * To assess the safety and tolerability of givinostat versus placebo administered chronically in DMD subjects * To evaluate the PK profile of givinostat administered chronically in DMD subjects * To evaluate the impact on quality of life (QoL) and activities of daily living of givinostat versus placebo administered chronically.

Conditions

  • Duchenne Muscular Dystrophy

Interventions

  • givinostatDrug

    The oral suspension of givinostat (10 mg/mL) was to be dosed in fed condition as described below: Givinostat or placebo starting dose * \> or =10 and \< 12.5 kg of weight: 13.3 mg bid = 1.3 ml oral suspension bid * \> or =12.5 and \< 20 kg: 16.7 mg bid =1.7 ml oral suspension bid * \> or = 20 and \< 25 kg: 20 mg bid = 2.0 ml oral suspension bid * \> or = 25 and \< 30 kg: 23.3 mg bid = 2.3 ml oral suspension bid * \> or = 30 and \< 40 kg: 26.7 mg bid = 2.7 ml oral suspension bid * \> or = 40 and \< 50 kg: 33.3 mg bid = 3.3 ml oral suspension bid * \> or = 50 and \< 60 kg: 36.7 mg bid = 3.7 ml oral suspension bid * \> or = 60 and \< 70 kg: 40 mg bid = 4 ml oral suspension bid * \> or = 70 kg: 46.7 mg bid = 4.7 ml oral suspension bid

  • placeboDrug

    The oral suspension of placebo, manufactured to mimic givinostat, was to be dosed in fed condition as described for givinostat.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Change From Baseline in 4 Standard Stairs (4SC) Climb After 18 Months of TreatmentTime frame: Baseline and 18 months

Locations

42 sites in 11 countries. Site status is shown where the registry gives one.

  • Neuromuscular Research Center UC Davis Department of Physical Medicine and Rehabilitation

    Davis, California

  • Rady Children's Hospital center - UCSD Department of Neuroscience

    San Diego, California

  • Children's Hospital Colorado

    Aurora, Colorado

  • Connecticut Children's Medical Center - Division Neurology

    Hartford, Connecticut

  • Child Health Research Institute - Department of Pediatrics

    Gainesville, Florida

  • Nemours Children's Hospital

    Orlando, Florida

  • MD Rare Disease Research, LLC

    Atlanta, Georgia

  • University of Iowa Children's Hospital

    Iowa City, Iowa

  • University of Minnesota - Department of Neurology

    Minneapolis, Minnesota

  • Washington University School of Medicine in St Louis - Department of Neurology

    St Louis, Missouri

  • Shriners Hospitals for Children

    Portland, Oregon

  • The Children's Hospital of Philadelphia Colket Translational Research Building

    Philadelphia, Pennsylvania

  • Virginia Commonwealth University Childrens Hospital of Richmond at Virginia Commonwealth University

    Richmond, Virginia

  • University Hospitals Leuven, Neuromuscular Reference Centre, Child Neurology

    Leuven, Belgium

  • Hospital de La Citadelle, Centre de Référence des Maladies Neuromuscolaires (CRMN)

    Liège, Belgium

  • Kinsmen Research Centre - Alberta Children's Hospital - Alberta Health Services

    Calgary, Alberta, Canada

  • The University of British Columbia, Children's and Womens Health Centre of BC Branch

    Vancouver, British Columbia, Canada

  • Holland Bloorview Kids Rehabilitation Hospital

    Toronto, Ontario, Canada

  • CHU de Nantes - Hotel-Dieu - Hopital Nord Laennec, rez-de-chausse haut ail Ouest

    Nantes, France

  • Hopital Armand Trousseau I-Motion, Plateforme d'essais cliniques pédiatriques

    Paris, France

  • Universitatsklinikum Essen - Kinder und Jugendmedizin Neuropadiatrie

    Essen, Germany

  • Klinik un Policlinik fur Kinder und Jugendmedizin - Universitatsklinikum Hamburg Eppendorf

    Hamburg, Germany

  • Klinikum der Uniersitat Munchen - Campus Innenstadt

    München, Germany

  • Institute of Neurology - Schneider Children's Medical Center of Israel Kaplan, 14

    Petah Tikva, Israel

  • IRCCS Istituto G.Gaslini, U.O.S.D. Centro Traslazionale di Miologia e Patologie Neurodegenerative

    Genova, Italy

  • A.O.U. Policlinico G. Martino, U.O.C. Neurologia e Malattie Neuromuscolari

    Messina, Italy

  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, UOS di Neurologia Pediatrica

    Milan, Italy

  • Fondazione IRCCS Istituto Neurologico Carlo Besta

    Milan, Italy

  • Centro Clinico NeMO Fondazione Serena ONLUS Area SUD

    Milan, Italy

  • Ospedale Pediatrico Bambin Gesù, Malattie Neuromuscolari e Neurodegenerative

    Roma, Italy

  • Fondazione Policlinico Universitario "A.Gemelli", UOC Neuropsichiatria Infantile

    Roma, Italy

  • Leiden University Medical Center LUMC

    Leiden, Netherlands

  • Radboud University Medical Centre

    Nijmegen, Netherlands

  • Clinic of Neurology and Psychiatry for Children and Youth - Neurology Department Dr. Subotic 6a,

    Belgrade, Serbia

  • Hospital Materno-Infantil - Passeig de la Vall d'Hebron

    Barcelona, Spain

  • Hospital Universitario Virgen del Rocio

    Seville, Spain

  • Hospital Universitari i Politécnic de la Fe - Servicio Neurologia

    Valencia, Spain

  • Hospital Sant Joan de Déu - Neuromuscular Pathology Unit

    Esplugues de Llobregat, Barcelona, Spain

  • Alder Hey Children's Hospital NHS Trust

    Liverpool, United Kingdom

  • UCL Great Ormond Street Institute of Child Health, Dubowitz Neuromuscular Centre and MRC Centre for NMD

    London, United Kingdom

Showing 40 of 42 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.